---
title: "Pfizer (PFE) stock news, pipeline, cash and catalysts"
url: "https://aibio.space/companies/pfizer-pfe/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Pfizer news for investors: Pfizer is a US drugmaker that sells medicines and vaccines for cancer, heart disease, infections, inflammation and rare diseases."
---

Desk view · Opinion · Updated Oct 22, 2026

## Pfizer has cut its way to stability, but growth after Eliquis still rests on phase 3 bets

Pfizer has stabilized its business with growing non-COVID sales, a strong Padcev franchise and more than $10 billion in cost cuts. Growth after the Eliquis cliff depends on obesity and oncology programs that have not yet produced late-stage data, and the sigvotatug vedotin miss weakened the Seagen story.

Read the full desk view

aibio.space Investor Rank · Opinion

**5** /10 Neutral view

Padcev and cost cuts have stabilized the business, but heavy debt, the Eliquis cliff and a Seagen ADC miss leave growth resting on unproven phase 3 bets.

- **Technology**: 1/2

- **Odds**: 1/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 1/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Two bought platforms.** Padcev is a proven ADC winner, while the next Seagen ADC failed and obesity is still in phase 3.

- **Odds**: **Good near term, unproven long term.** Talzenna's FDA decision is due in Q4 2026, but berobenatide and the PD-1 x VEGF bispecific lack late-stage data.

- **Balance sheet**: **Profitable but indebted.** About $11.7 billion in cash and short-term investments against $63.2 billion of debt at June 28, 2026.

- **Main risk**: **Patent cliff timing.** Eliquis loses protection before obesity and new oncology drugs can scale, with growth seen returning from 2028.

- **Watch next**: **ESMO data, October 23 to 27.** Then third-quarter results on November 3 and the Talzenna FDA decision in Q4.

## Top news on Pfizer

1. 2025-04-29 Distress [Pfizer expands cost realignment program, adds $1.2 billion in expected savings](https://aibio.space/news/pfizer-expands-cost-realignment-program-adds-1-2-billion-expected/) Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program.

## Dates

**October 23 to 27, 2026**
45 abstracts at ESMO in Madrid, including full SigVie-002 data and PF-08634404 phase 2 data [Source](https://s206.q4cdn.com/795948973/files/doc_news/Pfizer-Advances-Todays-Cancer-Care-and-Tomorrows-Potential-Breakthroughs-at-ESMO-2026.pdf)

**November 3, 2026**
Third-quarter 2026 results, call at 10:00 a.m. EST [Source](https://s206.q4cdn.com/795948973/files/doc_events/2026/Nov/03/Pfizer-Invites-Public-Q3-2026-Earnings_FINAL.pdf)

**Fourth quarter 2026**
FDA decision on Talzenna plus Xtandi in HRR-altered mCSPC [Source](https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-pfizers-talzenna-plus-xtandi)

**2026**
Start of 10 phase 3 studies of berobenatide [Source](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide)

## The money

$976 million in cash and cash equivalents plus $10.72 billion in short-term investments at June 28, 2026, against about $63.2 billion of total debt. No runway guidance; the company is profitable. [Source](https://www.sec.gov/Archives/edgar/data/0000078003/000007800326000095/pfe-20260628.htm)

Q2 2026 revenue was $15.0 billion, up 3%. 2026 revenue guidance raised at the midpoint to $60.5 billion to $62.5 billion. [Source](https://www.biospace.com/press-releases/pfizer-reports-second-quarter-results-and-raises-midpoint-of-2026-revenue-guidance)

## Risks on the record

- Eliquis is nearing the end of its patent life, and growth is not expected to return to a stronger pace until 2028. [Source](https://pharmaphorum.com/news/pfizer-targets-25bn-more-cost-savings)
- Sigvotatug vedotin missed its phase 3 survival goal, leading to a $3.8 billion impairment and raising questions about the Seagen pipeline. [Source](https://www.bnnbloomberg.ca/business/company-news/2026/08/05/pfizer-beats-earnings-estimates-targets-us25-billion-in-additional-cost-cuts/)
- Debt of about $63.2 billion against about $11.7 billion in cash and short-term investments limits large acquisitions. [Source](https://www.sec.gov/Archives/edgar/data/0000078003/000007800326000095/pfe-20260628.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Pfizer?

5 out of 10, our neutral view. Padcev and cost cuts have stabilized the business, but heavy debt, the Eliquis cliff and a Seagen ADC miss leave growth resting on unproven phase 3 bets. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What is Pfizer's 2026 revenue guidance?

On August 4, 2026, Pfizer raised the midpoint of its 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion. It kept adjusted earnings guidance at $2.80 to $3.00 per share. [Source](https://www.biospace.com/press-releases/pfizer-reports-second-quarter-results-and-raises-midpoint-of-2026-revenue-guidance)

### What is berobenatide?

Berobenatide is a GLP-1 receptor agonist peptide that Pfizer gained through its Metsera acquisition and is developing for monthly dosing in obesity. Pfizer plans 10 phase 3 studies in 2026. [Source](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide)

### Why did Pfizer take a $3.8 billion impairment in 2026?

BNN Bloomberg reported that the second-quarter GAAP loss included a $3.8 billion impairment on sigvotatug vedotin. The lung cancer ADC failed to improve overall survival against docetaxel in the phase 3 SigVie-002 trial. [Source](https://www.bnnbloomberg.ca/business/company-news/2026/08/05/pfizer-beats-earnings-estimates-targets-us25-billion-in-additional-cost-cuts/)

### Is Padcev approved for muscle-invasive bladder cancer?

Yes. In July 2026 the FDA approved Padcev with Keytruda before and after surgery for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility. [Source](https://www.biopharminternational.com/view/fda-approves-padcev-plus-keytruda-as-first-platinum-free-regimen-for-muscle-invasive-bladder-cancer)

### When does Pfizer report third-quarter 2026 earnings?

Pfizer will issue its third-quarter 2026 report on the morning of November 3, 2026, with an analyst call at 10:00 a.m. EST. [Source](https://s206.q4cdn.com/795948973/files/doc_events/2026/Nov/03/Pfizer-Invites-Public-Q3-2026-Earnings_FINAL.pdf)

### What is the latest Pfizer (PFE) stock news?

Our latest story on Pfizer, dated Apr 29, 2025: "Pfizer expands cost realignment program, adds $1.2 billion in expected savings". Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program. [Source](https://aibio.space/news/pfizer-expands-cost-realignment-program-adds-1-2-billion-expected/)

### How much cash does Pfizer have?

From our story of Apr 29, 2025: It paid $2.4 billion in cash dividends, or $0.43 per share. [Source](https://aibio.space/news/pfizer-expands-cost-realignment-program-adds-1-2-billion-expected/)

### Is Pfizer in financial distress?

Our latest distress story, dated Apr 29, 2025: "Pfizer expands cost realignment program, adds $1.2 billion in expected savings". Pfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program. [Source](https://aibio.space/news/pfizer-expands-cost-realignment-program-adds-1-2-billion-expected/)

### What is Pfizer's market cap?

We do not publish live share prices. In its annual report, Pfizer, Inc. put the market value of shares held by non-affiliates (public float) at $138.00 billion as of Jun 29, 2025. Source

### Is Pfizer a smaller reporting company?

SEC records list Pfizer, Inc.'s filer category as: Large accelerated filer. Source

### Where is Pfizer headquartered?

SEC records list its business address as 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192. Source

### When does Pfizer's fiscal year end?

Pfizer, Inc.'s fiscal year ends on December 31, per SEC records. Source

### What did Pfizer last file with the SEC?

Its most recent filing in our record is a 10-Q filed 2026-08-04. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm)

### What was Pfizer called before?

SEC records list these former names: PFIZER INC. Source

## Legal and investor matters

Checked against Pfizer filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Pfizer's 10-Q filed 2026-08-04 (Note 12A, Legal Proceedings) lists categories of legal contingencies including patent litigation, product litigation, commercial and other matters, and government investigations. [Source](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm)

1. 2026-08-04 Litigation Pfizer reaches agreement in principle in Chantix class litigation Pfizer's 10-Q says putative class actions filed from August 2021 after the voluntary Chantix recall over a nitrosamine were consolidated in a multidistrict litigation in the Southern District of New York. Plaintiffs say they suffered economic harm and seek to represent nationwide and state classes. In March 2026 the parties reached an agreement in principle to resolve the litigation on terms Pfizer describes as not material. It needs final court approval. U.S. District Court for the Southern District of New York (MDL) · Status: settled [Pfizer Form 10-Q filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm)
2. 2026-08-04 Litigation Pfizer reaches agreement in principle in Depo-Provera MDL Pfizer reports lawsuits in federal and state courts alleging that women who used injectable Depo-Provera for contraception developed meningioma. The federal cases were transferred in February 2025 to a multidistrict litigation in the Northern District of Florida. In June 2026 Pfizer reached an agreement in principle with plaintiff leadership that it expects to resolve a substantial majority of the pending MDL cases, on terms it says are not material to its liquidity or financial condition. U.S. District Court for the Northern District of Florida (MDL) · Status: pending [Pfizer Form 10-Q filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm)
3. 2026-08-04 Litigation State attorneys general antitrust suits over Greenstone generics continue Pfizer's 10-Q describes complaints filed in 2019 and 2020 by attorneys general of more than 50 states and territories in the District of Connecticut against pharmaceutical companies including Pfizer and its former generics subsidiary Greenstone. The complaints allege anticompetitive conduct in violation of antitrust and consumer protection laws. The state cases were transferred back to Connecticut in April 2024, and related private suits sit in a Pennsylvania multidistrict litigation. U.S. District Court for the District of Connecticut · Status: pending [Pfizer Form 10-Q filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm)
4. 2026-08-04 Litigation Pfizer settles Vyndaqel and Vyndamax patent suits; generic Vyndamax launch permitted from June 2031 Pfizer reports that in March 2026 it settled the Vyndaqel patent case, and in April 2026 it settled three Vyndamax cases, with generic filers in the District of Delaware. Under the settlements, the generic companies may launch generic Vyndamax capsules on 2031-06-01, subject to the outcome of other litigation. An action against Apotex relating to Vyndamax is ongoing. U.S. District Court for the District of Delaware · Status: settled [Pfizer Form 10-Q filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm)
5. 2026-08-04 Regulatory Pfizer 10-Q lists DOJ and SDNY requests on its India operations; Pfizer has produced records In its government investigations discussion, Pfizer's 10-Q says that in March 2020 it received an informal request from the U.S. Department of Justice's Consumer Protection Branch for documents on its manufacturing operations in India. In April 2020 it received a similar request from the U.S. Attorney's Office for the Southern District of New York regarding a civil investigation concerning its facilities in India. Pfizer says it has produced records pursuant to these requests. Status: pending [Pfizer Form 10-Q filed 2026-08-04](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm)
6. 2026-04-27 Governance Shareholders reject independent chair proposal at 2026 annual meeting Pfizer reported the results of its 2026 annual meeting in a Form 8-K filed 2026-04-27. A shareholder proposal to adopt an independent chair policy was not approved. It received 1,015,206,372 votes for and 2,509,042,021 votes against, with 32,354,566 abstentions and 941,392,137 broker non-votes. The same filing reports the results of the other items voted on at the 2026 annual meeting. [Pfizer Form 8-K filed 2026-04-27](https://www.sec.gov/Archives/edgar/data/78003/000007800326000044/pfe-20260423.htm)
7. 2025-11-21 Financing Pfizer completes multi-tranche U.S. dollar notes offering On 2025-11-21 Pfizer completed a public offering of seven series of notes. They included $500,000,000 of floating rate notes due 2027, $1,250,000,000 of 4.500% notes due 2032, $1,250,000,000 of 4.875% notes due 2035 and $500,000,000 of 5.700% notes due 2065. Pfizer's 8-K filed that day reports the offering under Item 8.01. [Pfizer Form 8-K filed 2025-11-21](https://www.sec.gov/Archives/edgar/data/78003/000119312525291406/d80089d8k.htm)
8. 2025-11-13 Litigation Pfizer completes Metsera acquisition; Pfizer had sued Metsera and Novo Nordisk in Delaware Pfizer completed its acquisition of Metsera on 2025-11-13 at $65.60 per share in cash plus a contingent value right of up to $20.65 per share, an enterprise value of about $7.0 billion. In October and November 2025 Pfizer filed lawsuits against Metsera, Novo Nordisk and related parties in the Delaware Court of Chancery and the federal court in Delaware over a competing proposal Novo made on 2025-10-25. Pfizer's 10-Q describes claims including breach of contract and tortious interference. Delaware Court of Chancery; U.S. District Court for the District of Delaware [Pfizer Form 8-K filed 2025-11-13](https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/pfe-20251113.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Berobenatide (PF'3944, formerly MET-097i) | Obesity and weight-related conditions (monthly GLP-1) | Phase 3 (10 studies planned in 2026) [Source](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide) |
| Talzenna + Xtandi | HRR gene-altered metastatic castration-sensitive prostate cancer | sNDA under FDA priority review, decision Q4 2026 [Source](https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-pfizers-talzenna-plus-xtandi) |
| PF-08634404 (PD-1 x VEGF bispecific) | First-line NSCLC, colorectal and endometrial cancer | Registrational studies ongoing [Source](https://s206.q4cdn.com/795948973/files/doc_news/Pfizer-Advances-Todays-Cancer-Care-and-Tomorrows-Potential-Breakthroughs-at-ESMO-2026.pdf) |
| Sigvotatug vedotin + pembrolizumab | First-line NSCLC with PD-L1 of at least 50% | Phase 3 (monotherapy missed in second line) [Source](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-3-results-sigvotatug-vedotin) |
| Padcev + Keytruda | Muscle-invasive bladder cancer | FDA approved July 2026 [Source](https://www.biopharminternational.com/view/fda-approves-padcev-plus-keytruda-as-first-platinum-free-regimen-for-muscle-invasive-bladder-cancer) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Pfizer's filings back its numbers, but the obesity and lung-cancer messages are more upbeat than the data behind them

Pfizer's second-quarter release and 10-Q agree on the financials, and the release leads with the reported loss and the $4.3 billion of impairments. The softer spots are in the pipeline messaging: a lung-cancer ADC that missed its survival goal was described in terms of a subgroup, and the obesity headline rests on an exploratory weekly-dose figure.

1. Press release vs filing · weight high Sigvotatug: subgroup optimism vs a missed primary endpoint and a $3.8 billion write-down **The company said:** "Although the study did not meet its overall survival endpoint, in second-line patients the data suggest a clinically meaningful survival benefit" [source](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-3-results-sigvotatug-vedotin) **The record says:** The 10-Q states the study "did not meet its primary endpoint of a statistically significant improvement in overall survival compared to docetaxel" and records "$ 3.8 billion in impairments of IPR&D assets, associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results." [source](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm) **Our view:** The June release is open that the primary endpoint was missed, but the second-line trend language sits beside no hazard ratio or survival numbers. The accounting treatment shows how Pfizer itself valued the result: as an impairment, not a delay.
2. Science · weight medium Berobenatide headline weight loss is a non-placebo-adjusted, exploratory figure **The company said:** "non-placebo-adjusted weight loss of 15.9%" [source](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide) **The record says:** The same release says the figure came from participants who escalated from placebo to 2.4 mg weekly berobenatide, with "no plateau observed at 32 weeks on berobenatide," and that "Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026." The release does not give enrollment numbers or discontinuation rates for the phase 2b trials, describing GI events and discontinuations only as "low." [source](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide) **Our view:** The headline is a weekly-dose number from an extension part, while the title promotes monthly dosing. Without placebo-adjusted data, sample sizes or numeric discontinuation rates, cross-trial comparisons with other obesity drugs are not possible from this release.
3. Press release vs filing · weight low Reported loss and adjusted profit are both prominent **The company said:** "Second-Quarter 2026 Reported Loss Per Share of $(0.04), and Adjusted Diluted EPS of $0.77" [source](https://www.biospace.com/press-releases/pfizer-reports-second-quarter-results-and-raises-midpoint-of-2026-revenue-guidance) **The record says:** The release adds "Reported Loss Per Share Reflects $4.3 Billion in Non-Cash Intangible Asset Impairments." The 10-Q carries the same impairments, including $525 million for Oxbryta after "there was no viable pathway to return Oxbryta to the market in the U.S." [source](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm) **Our view:** Pfizer puts GAAP and adjusted figures in the same headline and says what drove the gap, so there is no mismatch here. The Oxbryta and sigvotatug charges together total $4.3 billion, which is what the 'adjusted' number leaves out of the reported loss.
4. Legal and disclosure record · weight medium Product, patent and government matters disclosed; no securities class action in the legal note **The record says:** Note 12A lists Zantac cases in an MDL in the U.S. District Court for the Southern District of Florida, Chantix putative class actions in an MDL in the Southern District of New York ("In March 2026, the parties reached an agreement in principle to resolve the litigation on terms not material to Pfizer"), Depo-Provera cases ("In June 2026, we reached an agreement-in-principle with plaintiff leadership in the Depo-Provera MDL") and DOJ requests relating to its India manufacturing operations (March 2020). [source](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm) **Our view:** These are documented matters in the filing, not findings of wrongdoing. The legal note describes no securities class action against Pfizer in the sections we read.

Documents we compared

- [Pfizer Form 10-Q for the quarter ended June 28, 2026](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm) 2026-08-04
- [Pfizer second quarter 2026 results release](https://www.biospace.com/press-releases/pfizer-reports-second-quarter-results-and-raises-midpoint-of-2026-revenue-guidance) 2026-08-04
- [Pfizer topline phase 3 sigvotatug vedotin release](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-3-results-sigvotatug-vedotin) 2026-06-22
- [Pfizer berobenatide phase 2b release](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide) 2026-06-05

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:PFE on TradingView](https://www.tradingview.com/symbols/NYSE-PFE/).

## SEC filings and registration

- **SEC name**: Pfizer Inc

- **CIK**: 78003

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: PFE (NYSE)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192

- **Phone**: 2127332323

- **Shares outstanding**: 5,699,673,589 as of 2026-07-29 (10-Q filed 2026-08-04)

- **Former names**: PFIZER INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-20260804.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/78003/000007800326000087/pfe-20260618.htm) filed 2026-06-18
- [8-K](https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm) filed 2026-06-18
- [10-Q](https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/pfe-20260329.htm) filed 2026-05-05
- [8-K](https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-20260505.htm) filed 2026-05-05
- [8-K](https://www.sec.gov/Archives/edgar/data/78003/000007800326000044/pfe-20260423.htm) filed 2026-04-27
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/78003/000007800326000033/pfe-20260312.htm) filed 2026-03-12

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/pfizer-pfe/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pfizer (PFE) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/pfizer-pfe/